



Combination Therapy against Multidrug-Resistant Pathogens

Guest Editors:

Dr. Mao Hagihara

Department of Molecular
Epidemiology and Biomedical
Sciences, Aichi Medical
University, Aichi, Japan

Dr. Hideo Kato

1. Department of Pharmacy, Mie University Hospital, Mie 5148507, Japan
2. Department of Clinical Pharmaceutics, Mie University Graduate School of Medicine, Mie 5148507, Japan
3. Department of Clinical Infectious Diseases, Aichi Medical University, Aichi 4801195, Japan

Deadline for manuscript
submissions:

closed (30 June 2025)

Message from the Guest Editors

Dear Colleagues,

Antibiotic combination therapy is often used to improve clinical efficacy in patients where a given therapy is thought to have limitations when used alone. The majority of the data evaluating combination therapy have been determined using in vitro techniques or animal models of infection. Through analyses of this information coupled with the available clinical data, albeit limited, it is possible to identify a number of clinical situations where combination therapy can be supported. When used appropriately with optimal doses, combination therapy may offer an excellent opportunity to maximize clinical outcomes, particularly in the face of antibacterial resistance. Therefore, clinicians should carefully evaluate the risks and potential benefits before adding additional antibiotics to standard single-drug therapies.

This Special Issue invites researchers interested in antibacterial combination therapy against antibacterial resistance pathogens to optimize antimicrobial use with special emphasis on assisting with the development of antibacterial treatment guidelines.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi